Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Hexagon Purus enters into framework agreement to deliver hydrogen distribution systems in Europe

(Oslo, Norway, 14 October 2022) Hexagon Purus ASA (“Hexagon Purus”), through its wholly owned subsidiary Wystrach GmbH, a leading hydrogen systems supplier, has secured a framework agreement for delivery of hydrogen distribution systems to a leading European producer of green hydrogen.   Hexagon Purus’ hydrogen distribution systems including its type 4 hydrogen cylinders will be used to deliver hydrogen for transportation and industrial applications in Europe. The minimum value of the framework agreement is approximately EUR 9.7 million (approximately NOK 97 million).   Driving Energy

Invitation – Third quarter results presentation 2022

Troax Group´s report for the third quarter 2022 will be published at 12:30 CET, October 25.Thomas Widstrand, President and CEO, will present the financial results on a conference call the same day at 16:30 CET.The conference will be held in English. The report and a presentation will be available on the company’s websitetroax.com/global/en/investor/financial-reports  Please join the event conference 5 minutes prior to the start time using the Conference PIN below. Conference PIN : 1445834 Stockholm Stockholm: +46 (0)

Viking Line Abp: M/V Amorella is handed over to Corsica Ferries SAS

Viking Line Abp    OTHER INFORMATION  DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE  14th of October 2022 2:30 PMM/V Amorella is handed over to Corsica Ferries SAS With references to the previous stock exchange release the 5[th] of August 2022, M/V Amorella was handed over yesterday evening 13th of October 2022, to Corsica Ferries SAS. The name of the vessel will be M/V Mega Victoria after reflagging. Viking Line Abp Jan HansesPresident and CEO

AcadeMedia comments on the incoming government's agreement concerning schools

In relation to the agreement made by the incoming government (Tidö Agreement), AcadeMedia submits the following comment:   - We welcome many of the proposals in the Tidö Agreement and look forward to the proposals being investigated and implemented. Many of the proposals AcadeMedia has developed over the years are included here, says AcadeMedia’s CEO Marcus Strömberg. - We think it is very good that the work that we have called the Independent school reform 2.0, is now actually getting underway. In the proposals, there are very good opportunities to develop long-term rules for the

Teollisuuden Voima Oyj Interim Report January–September 2022

During the first three quarters of 2022, Teollisuuden Voima’s (TVO) electricity generation at the Olkiluoto 1 (OL1) and Olkiluoto 2 (OL2) plant units continued safely and reliably.The electricity production of the Olkiluoto 3 EPR plant unit (OL3) started on Saturday, 12 March 2022. In September, OL3's test production proceeded first to tests at an 80 percent power level, and then at the end of the month to tests at full power. According to information received from the Plant Supplier in June 2022, OL3’s regular electricity production starts in December 2022. OL3 significantly improves

CVS Group plc chooses Nordhealth as Practice Management Software Partner

Provet Cloud to be utilized by one of the largest integrated veterinary service providers in EuropeProvet Cloud , the cloud-based practice management solution from Nordhealth, announced today that CVS Group plc (“CVS”) will implement Provet Cloud’s practice management software across all of its veterinary practices. CVS is an AIM-quoted fully-integrated veterinary service provider in Europe, operating c.500 veterinary surgeries throughout the UK, the Republic of Ireland, and the Netherlands. Employing  c.2,100 veterinarians and c.3,000 nurses, the success of

BEWI – Approval and publication of a prospectus supplement

Reference is made to the stock exchange announcement published by BEWI ASA ("BEWI" or the "Company") on 1 October 2021, 15 October 2021, and 1 July 2022 regarding the Company's acquisition of Jackon Holding AS ("Jackon") (the "Jackon Transaction"). Reference is further made to the stock exchange announcement on 21 February 2021 regarding the approval and publication of a prospectus prepared by BEWI for the listing of the consideration shares to be issued in connection with the closing of the Company's acquisition of Jackon (the "Prospectus"). The Financial Supervisory Authority of Norway

Supply agreement signed with Region Östergötland for wound healing products

Region Östergötland has announced that they intend to sign a direct purchase agreement for items within S2Medical AB (publ)’s wound healing portfolio. The region has not yet announced an estimated quantity or duration of the contract. Information regarding quantity and duration may be announced after the agreement is signed by both parties.   S2Medical's wound healing portfolio consists of several different products that facilitate all the phases of wound healing and contribute to a significantly improved quality of life, for the patients and a significantly reduced cost of care.

Publication of Raute Corporation's interim report and invitation to a briefing

RAUTE CORPORATION INVESTOR NEWS 14 OCTOBER 2022PUBLICATION OF RAUTE CORPORATION'S INTERIM REPORT AND INVITATION TO A BRIEFING   Raute Corporation will publish its Interim Report for January 1-September 30, 2022 (9 months) on Friday, October 21, 2022 at about 9 a.m. Finnish time. A briefing for analysts, investors and the media will be organized on the same day October 21, 2022 at 2:00 - 3:00 p.m.   Venue: Scandic Simonkentta Hotel, Simonkatu 9, Helsinki.   Please inform of your participation in the briefing at the latest on Wednesday, October 19, 2022 to Raute

Cantargia reaches recruitment milestone and focuses nadunolimab development on upcoming randomized studies

Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced that the clinical trials CAPAFOUR and CESTAFOUR have enrolled enough patients to halt recruitment. Preliminary results show acceptable safety of the chemotherapy combinations with Cantargia’s lead asset, the IL1RAP-binding antibody nadunolimab (CAN04), as well as signs of efficacy in a cohort of non-small cell lung cancer (NSCLC) patients treated with nadunolimab and gemcitabine/cisplatin in CESTAFOUR. Consequently, clinical development of nadunolimab will focus on planned randomized trials in the lead indications. Additionally,

Flowscape receives expansion order with global customer

A large global customer is expanding its installation to meet the hybrid way of working  by expanding Flowscape's solution to additional offices and more users. The order value for the first year is SEK 1,220,000 (111,000 Euro) and thereafter SEK 77,400 (7,002 Euro) annually recurring."We have been working with the customer since 2016 and supporting them in different phases. Before the pandemic, there was a great focus on solutions for efficient room booking , during the pandemic the interest changed

EQT Infrastructure broadens investor base in GlobalConnect

· EQT Infrastructure welcomes Mubadala as an investor in GlobalConnect  · The broadened investor base adds new resources and expertise, supporting GlobalConnect’s long-term ambition to increase societies’ digital connectivityEQT is pleased to announce that the EQT Infrastructure III and IV funds (“EQT Infrastructure”) have signed an agreement to sell a minority stake in GlobalConnect (the “Company”) to Mubadala Investment Company (“Mubadala”). Having been invested in the Company since 2017, EQT Infrastructure will remain as the largest owner following the closing of the transaction.

AegirBio announces first clinical saliva TDM study in US

PRESS RELEASE                      October 14, 2022 AegirBio is pleased to announce the initiation of a clinical study to evaluate saliva based measurements of natalizumab in multiple sclerosis patients. The goal of the study is to confirm that our novel saliva calibration method can be used to accurately measure therapeutic drug levels in saliva as compared to blood. The study is being performed in collaboration with Dr. John Foley at the Rocky Mountain MS Clinic in Salt Lake City.“To our knowledge, this is the first such study of its kind and will hopefully open the door to non-

Members of the Nomination Committee for Episurf Medical’s Annual General Meeting in 2023

In accordance with decision by the Annual General Meeting, Episurf Medical’s Nomination Committee shall consist of four members. The members are selected by the three largest shareholders in the company that wish to participate in the committee. In addition, the Chairman of the Board is to be appointed to the Nomination Committee. In accordance with the above principles, the Nomination Committee consists of the following four members: · Dennis Stripe, Chairman of the Board of Episurf Medical AB · Sebastian Jahreskog · Johan Wadell, representing Andra AP-fonden · Robert

Waystream’s best ever quarter

The third quarter was Waystream's best ever, with revenue growth of 89% and a 236% improvement in operating result compared to 2021. Underpinning this is that we continue to see great demand for our products, from both new and existing customers, while simultaneously increasing the production rate as planned in order to meet the increased demand. We have secured more new customers during the first nine months of the year than in all of 2020 and 2021 combined, while not losing a single customer. It is especially gratifying that at the beginning of September we were able to present a

Enrolment completed and recommended phase II dose reached for OXC-101

Oxcia AB, today announced that it has completed enrollment and evaluation of the last patient in the MASTIFF Phase I clinical trial of OXC-101 in escalating doses for the treatment of patients with advanced solid malignant tumours. The recommended phase II dose has now been determined.  Study results will be reported the coming months.   “Completing enrolment in the MASTIFF study and determining the Phase 2 Recommended Dose are very significant milestone for our company and allows us to finalize planning of our phase II study” said Austin Smith, M.D, Chief Medical Officer, Oxcia. “We

Bonava publish restated comparative numbers due to the divestment of St. Petersburg

Bonava announced on the 7th of October that we have entered into an agreement to divest Bonava’s subsidiaries in Russia. As a result, the St. Petersburg operations will be reported as discontinued operations from the third quarter 2022. Restated comparative numbers have been published on Bonavas website.In the third quarter 2022 the result of the operations in St. Petersburg will be reported as result from discontinued operations. Bonava Group financial data for prior periods have been restated showing group figures without the St. Petersburg operations. Restated comparative numbers have

Dates for SSAB’s financial reports in 2023

Dates for SSAB’s financial reports in 2023 and the AGM. January 27, 2023             Year-end report for 2022April 26, 2023                  Q1 – Interim report for January-March 2023July 21, 2023                   Q2 – Interim report for January-June 2023October 25, 2023             Q3 – Interim report for January-September 2023 Reports are published at 7.30am CET/CEST on the release date unless otherwise announced. The Annual Report for 2022 will be published during week 12. The Annual General Meeting 2023 will be held in Oxelösund on April 18, 2023. For

Merger with wholly owned subsidiary completed

Reference is made to previous announcements regarding the merger between Aker BP ASA ("Aker BP") and its wholly owned Dutch subsidiary ABP Energy Holding B.V ("AEH"). The merger has now been completed. Consequently, Aker BP has assumed all assets, rights and obligations of AEH, and AEH has simultaneously been dissolved. The merger has been executed without merger consideration and Aker BP’s share capital remains the same.

Presentation of 3[rd] quarter 2022 results

Atea ASA will present its 3[rd] quarter 2022 financial results on Thursday, 20 October 2022 at 08:00 CEST. The presentation will be held at Thon Hotel Vika Atrium, Munkedamsveien 45, Oslo, Norway. In addition to presenting the 3[rd] quarter 2022 results, the company will provide an update on the business. The quarterly report, presentation material, and webcast will be available at:https://www.atea.com/investors/financial-reports/ For further information, please contact:Robert Giori, CFO, Atea ASA, mobile (+47) 934 09 188  About AteaAtea is the leading supplier of IT

OrderYOYO raises ARR and EBITDA guidance for 2022

Company Announcement No. 34 -2022 OrderYOYO A/SInside Information   Copenhagen, October 14, 2022 Consolidated 2022 guidance raised As the merger with app smart progress successfully and due to strong performance in Q3 2022 despite difficult market conditions where OrderYOYO has been taking market share in all major markets consolidated guidance is raised again as follows: •          December 2022 annualized ARR guidance is raised from DKK 180-195m to DKK 185-200m •          EBITDA before other external costs full-year 2022 guidance is raised from DKK (10)-0m to DKK (5)

Artificial Solutions: Invitation to presentation of Q3 report 2022

Artificial Solutions® (SSME:ASAI ), the leading specialist in enterprise-strength conversational AI, will release the interim report for the third quarter of 2022 and new financial targets on Monday 17th October at 12:00 pm (CET).The full report and a brief presentation will be available on: www.investors.artificial-solutions.com/financial-reports. Conference Call – details Per Ottosson, CEO and Fredrik Törgren, CFO will present the financial results and new financial targets. The presentation

MapsPeople – Announcement of extraordinary general meeting

MapsPeople A/S | Notice convening extraordinary general meetingCompany Announcement No. 15 - 2022 Aalborg, October 14, 2022  Extraordinary general meeting of MapsPeople The board of directors hereby convenes to an extraordinary general meeting in MapsPeople A/S, to be held on 1 November 2022 at 16:00 CET on Stigsborgvej 60, 9400 Nørresundby  Agenda 1. Election of a new member of the board of directors 2. Any other business Re agenda item 1 The board of directors proposes that Michael Gram, current CEO of MapsPeople, is elected as a new member of the board of

Swiss Real Estate Award - Manufacturer Innovation: GF Piping Systems nominated with the Hycleen Automation System

The company received one of the three nominations for its Hycleen Automation System that makes drinking water systems safer and more energy efficient.The Hycleen Automation System by GF Piping Systems has been nominated for the category “Manufacturer Innovation” by the jury of the Swiss Real Estate Award. The submitted products were evaluated according to their innovation, sustainability, originality, service offers, customer benefits, the plausibility of their marketing and sales strategies, and their user-oriented architecture. GF Piping Systems developed the Hycleen Automation System

There are no items matching the current filter
There are no more items matching the current filter
Back to top